to explain the rise in Cr and ≥10% rise in serum cystatin levels from baseline at 24 h. Cr will be assessed at baseline and at 24, 48 and 72 h and CyC will be measured at baseline and at 24 h.

Results: After 48 hrs of CM exposure, Cr increase ≥0.5 mg/dL occurred in 29 patients (11.3%) whereas increase in CyC ≥10% at 24 hrs after CM exposure occurred in 66 patients (26.08%). The difference in mean Cr and baseline, 24 hrs and 48 hrs after CM exposure was not statistically significant whereas that between CyC at baseline and 24 h after CM exposure was significant. CyC detected CIN 24 hrs earlier as compared to Cr. Similarly the difference between GFR calculated by Cr equation was not statistically significant between pre and post CM exposure but the difference was significant when GFR was calculated using the combined equation. The risk of CIN was higher in patients with pre-existing CKD, diabetes, advanced age, haemodynamic instability, heart failure (LVEF < 40%), patients with ACS and higher contrast volumes.

Conclusions: The assessment of CyC at 24 hours after CM exposure allows an early diagnosis of CIN. Also CyC equation and the combined equation (Cr + CyC) for measurement of GFR accurately identified the patients with CIN even at 24 hrs after CM exposure, in contrast to Creatinine which took 48-72 hrs. Hence the management strategies for CIN can be started earlier by 24-48 hrs when CyC is used as a marker for CIN which would improve long term outcomes.

Pulmonary embolism – Single centre registry data

C. Anand*, S.S. Iyengar, C. Anindita, S. Siddharth, R. Roopa, C. Subash

Manipal Hospital, Bangalore, India

Background: Pulmonary embolism (PE) is one of the major cause of cardiovascular mortality. High index of suspicion is necessary for diagnosis. PE likelihood scoring is a useful clinical tool for risk stratification and management. This was a prospective registry to study the clinical features, clinical likelihood scoring, risk stratification and management of PE.

Methods: Consecutive cases hospitalized over a period of 3 years were studied. Revised Geneva score was applied to all cases of suspected pulmonary embolism. Most cases had PE confirmed by CT pulmonary angiography. Risk stratification (Pulmonary Embolism Severity Index from 2015) was used to guide the treatment strategy.

Results: There were 44 patients of pulmonary embolism, 26 being male. The mean age for male patients was 43.8 years and for females 55.4 years. Among 44 patients, 11 (25.0%) patients had surgery or immobilisation in the past 30 days, 15 (34.09%) patients had DVT. 4 (9.09%) patients had diabetes, 3 (6.81%) had hypertension. 6 (13.6%) patients were smokers. 37 (84.0%) patients had breathlessness. ECG revealed sinus tachycardia in 34 (77.2%). Echocardiogram showed dilated right atrium (RA) & right ventricle (RV) in 32 (72.7%) patients and RV dysfunction in 10 (22.7%) patients. The mean modified Geneva score was 8.18 for males and 9.7 for female. CT pulmonary angiography was done in 33 patients which confirmed PE in 32 cases. Risk stratification according to expected pulmonary embolism-related early mortality rate stratified 11 (25.0%) patients in high risk group, 27 (61.3%) patients in intermediate risk group & 6 (13.6%) patients in low risk group. 27 (61.3%) patients were thrombolysed with tenecteplase & 3 (6.8%) with reteplase. 1 patient had emergency surgical thrombo-endartectomy, recovering fully after an eventful post-operative period. Post-treatment most patients showed improvement.

Conclusion: Modified Geneva score along with imaging investigations helped in establishing diagnosis. Thrombolytic therapy in high risk cases and selected intermediate risk cases was safe and effective.

Assessment of short term effects of sildenafil therapy in patients with secondary pulmonary hypertension

P. Dwivedi*, V.S. Narain, R.K. Saran, S.K. Dwivedi, R. Sethi, S. Chandra, A. Pradhan, G.K. Chaudhary, P.K. Vishwakarma

Background: It is well proven that sildenafil improves pulmonary hemodynamics and exercise capacity in patients with primary pulmonary hypertension. However, the drug armamentarium for secondary pulmonary hypertension is limited. Sildenafil may also be helpful in this subgroup. Certain studies have shown promising results but none of the magnitude to promulgate new recommendations.

Methods: In this double-blind, placebo-controlled study, we randomly assigned 106 patients with symptomatic secondary PAH (idiopathic DCMP, heart failure with preserved EF, COPD, and other lung parenchymal disease, valvular heart disease) to placebo or sildenafil (53 in each group). Sildenafil was given orally 25 mg TID for 6 weeks. The primary end point was the change from baseline to week 6 in the distance walked in 6 minutes. We also assessed clinical improvement (improvement in 6 minute walk test, and NYHA functional class, change in Borg dyspnoea index) and change in hemodynamic parameters (PASP, LVEF).

Results: Of the 106 patients, included secondary PAH was due to COPD in 21 (19.8%), valvular heart disease in 53 (50%), heart failure with preserved EF in 16 (15%), idiopathic DCMP in 11 (10.2%) and other lung parenchymal diseases in 5 (5%). The mean increase in the distance walked after 6 weeks of therapy was 54 min sildenafil group and 13 m in placebo group $p = 0.04$. In the sildenafil group significantly greater number of patients improved by at least one functional class (23% vs 11%, $p = 0.003$). The mean NYHA class at 6 weeks was 2.0 ± 0.2 in the sildenafil group versus 2.8 ± 0.4 in the placebo group, $p = 0.02$. The mean PASP significantly decreased in the sildenafil group at 6 weeks (48 ± 6 mmHg), compared to placebo (58 ± 6 mmHg), $p = 0.02$. LVEF was higher in the sildenafil group, $60 \pm 10\%$ versus $55 \pm 10\%$ in the placebo group, but did not reach statistically significant difference.

Conclusion: Sildenafil improves exercise capacity, functional class, and hemodynamics in patients with PAH. PDE-5 inhibition may represent an important therapy for patients with secondary PAHif, the benefits observed in our study are confirmed in larger clinical trials.

Use of dabigatran versus warfarin in patients of atrial fibrillation at Asian heart hospital – An institutional based study

A. Amale*, G. Jagdale, N. Gautam, T. Suvarna

Asian Heart Institute & Research Centre Pvt. Ltd, Mumbai, India

Background: Atrial fibrillation increases the risks of stroke and death. Although warfarin reduces the risks of stroke and death, it increases the risk of hemorrhage along with its other drawbacks.

Dabigatran is a new oral direct thrombin inhibitor and has been proposed to overcome many pitfalls of warfarin therapy.

Method: In this study, we retrospectively studied 236 patients who had atrial fibrillation and were at risk of stroke who received fixed dose of Dabigatran 110 mg and adjusted-dose warfarin. Patients were followed up for a period of 2 years and stroke or systemic embolism was our primary end points.

Results: When rates of the primary outcome were considered which was 1.56% per year in the warfarin group, as compared with 1.33% per year in the group that received 110 mg of dabigatran (relative risk with dabigatran, 0.90; 95% confidence interval [CI], 0.72–1.09; $p < 0.001$ for non inferiority). Again the rate of major bleeding was 2.96% per year in the warfarin group, as compared with 2.11% per year in the group receiving 110 mg of dabigatran ($p = 0.005$). If the rate of hemorrhagic stroke was considered, it was 0.34% per year in the warfarin group, as compared with 0.09% per year with 110 mg of dabigatran ($p < 0.003$). Finally the mortality rate was 3.9% per year in the warfarin group, as compared with 3.15% per year with 110 mg of dabigatran ($p = 0.11$)

Conclusions: We observed in our study that, dabigatran given at a dose of 110 mg was associated with rates of stroke and systemic embolism that were similar and were non inferior to those associated with warfarin, as well as lower rates of major hemorrhage. Also many pitfalls of warfarin were covered well by Dabigatran and hence it's use in patients of atrial fibrillation with risk of stroke can be advocated.

Effect of vanadium supplementation on high fat diet induced hyperlipidemia

G. Subramanyam [1,*], Ramalingam [2], Veeranjaneyulu [3]

[1] Department of Cardiology, Narayana Medical Institutions, Chinta Reddy Palem, Nellore, India
[2] Department of Biochemistry, Narayana Medical Institutions, Chinta Reddy Palem, Nellore, India
[3] Animal Lab, Narayana Medical Institutions, Chinta Reddy Palem, Nellore, India

In mica mine workers in Nellore district the prevalence of ischemic heart disease and serum cholesterol levels are less in when compared to other rural population in our earlier studies. Vanadium content of mica and Blood levels of vanadium in mica workers is high compared to other rural population. Hence study in experimental animals is under taken in our laboratory to know the effect of vanadium.

Vanadium is an essential trace elements in certain animals and its role in humans is debated. Under physiological conditions vanadium predominantly exists in either an anionic form (vanadate) or a cationic form vanadyl. The vanadate is mainly bound to transferin and to a lesser extent to albumin. The present study aimed to know the effect of vanadium supplementation on high fat diet induced hyperlipidemia in experimental animals. In this study, New Zealand white breed male rabbits divided into three groups and each group consists of 6 in number.

Group I: Rabbits fed with standard diet.
Group II: Fed with 2% cholesterol diet.
Group III: Rabbits fed with group II diet and supplemented with 0.75 mg/kg of elemental vanadium as Sodium meta vanadate. Total cholesterol, LDL cholesterol and triglycerides were significantly decreased in Group III when compared to Group II after the experiment. HDL is similar in both groups. Present study shows antilipedemic effect of Vanadium in experimental rabbits. Supplementation of vanadium may prevent cardiovascular risk factor like Hyperlipidemia.

Role of serum ST2 as a prognostic marker in acute MI

Dattagupta Aditi, I. Sathyamurthy [*], G. Sengottuvelu, K.N. Srinivasan, Kirubakaran

Department of Cardiology, Apollo Hospital, Chennai, India

Introduction: ST2 is a biomarker which is a member of the interleukin (IL)-1 receptor family and exists in two forms, a transmembrane receptor (ST2L) as well as a soluble decoy receptor (sST2). Myocytes that are subjected to mechanical stress secrete ST2, that is associated with HF after STEMI.

Aims & objectives: To co-relate the level of ST2 on presentation and at discharge, with the clinical severity of the disease on presentation, the subsequent complications of ACS during the hospital stay and the occurrence of heart failure/adverse cardiovascular events (re-infarction/death) after discharge.

Inclusion & exclusion criteria:

1. Age more than 30 years.
2. Presenting within 24 hours of onset of symptoms.
3. Fulfilling the criteria for diagnosis of Acute MI.
4. Patients with PCI related and CABG related acute MI have been excluded.

Materials and methods: A prospective study is being done in patients admitted with ACS in Apollo hospital Chennai. Blood samples for ST2 are taken on presentation & at discharge. The sample is analysed using the 'Presage kit' provided by Critical diagnostics-Chennai Medipoint. A cut off of 35 ng/dl was used to label a sample as high ST2 level. Clinical history, biochemical tests and Echocardiography results are also documented.

Results: 42 patients admitted in Apollo Hospital, Chennai have been included so far. The clinical profile, ST2 levels, the clinical outcome and re-hospitalisations (if any) were documented.

Conclusion: The study is still in process and concrete conclusions cannot be drawn based on the existing samples. However high ST2 values were seen to be associated with increased mortality.

Serological correlation with cardiovascular manifestations of systemic lupus erythematosus patients in India

Imran Ahmed [1,*], Ananta Kumar Datta [2], Aniban De [3], Prasun Roy [4], Manoj Soren [4], Santanu Guha [5]

[1] Assistant Professor, Cardiology, Medical College, Kolkata, India
[2] Associate Professor, General Medicine, S.S.K.M Hospital, Kolkata, India
[3] RMO Cum Clinical Tutor, General Medicine, N.R.S Medical College, Kolkata, India
[4] RMO Cum Clinical Tutor, General Medicine, Burdwan Medical College, Kolkata, India
[5] Professor and Head, Cardiology, Medical College, Kolkata, India

Introduction: Cardiovascular (CV) involvement is common and a significant cause of morbidity and mortality in systemic lupus erythematosus (SLE). Auto-antibodies anti-dsDNA and antiphospholipids antibodies (APLA) are both pathogenic as well as serve a role as biomarker for diagnosis and severity. There are only very few reports of correlation of anti-dsDNA and/or APLA positivity